Product Details
ZIRABEV 25MG/ML 4ML SDV 1/EA
Manufacturer: Pfizer
MFG#: 00069-0315-01
NDC: 00069-0315-01
PID: 639475
Additional Information
| Product Name | Zirabev 25 mg/mL 4 mL SDV 1/Ea |
| Application | Treatment of various cancers |
| Active Ingredient | Bevacizumab-bvzr |
| Mechanism of Action | VEGF inhibitor preventing tumor angiogenesis |
| Dosage Form | Intravenous Injection |
| Strength | 25 mg/mL |
| Volume | 4 mL |
| Administration Route | Intravenous (IV) infusion |
| Dosing Schedule | Based on cancer type; typically every 2-3 weeks |
| Onset of Action | Reduction in tumor vascularization observed within weeks |
| Common Side Effects | Hypertension, proteinuria, bleeding, thromboembolic events |
| Precautions | Monitor for bleeding, hypertension, renal impairment, and wound healing complications |
| Packaging | Single-dose vial |
| Uses | Treatment of metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer |
Description
Zirabev (Bevacizumab-bvzr) 25 mg/mL, 4 mL single-dose vial, is a biosimilar monoclonal antibody indicated for the treatment of various cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer. It functions as an angiogenesis inhibitor by targeting vascular endothelial growth factor (VEGF), thereby preventing the formation of new blood vessels that supply tumors with oxygen and nutrients.
The active ingredient, bevacizumab-bvzr, binds to VEGF and inhibits its interaction with receptors on endothelial cells. By blocking VEGF signaling, Zirabev suppresses angiogenesis, reducing tumor vascularization and limiting metastatic potential.
Zirabev is administered as an intravenous infusion, with dosing regimens tailored to the specific cancer type being treated. Premedication may be required to minimize infusion-related reactions. Regular monitoring of blood pressure, renal function, and proteinuria is necessary due to the increased risk of hypertension, thromboembolic events, and impaired wound healing associated with VEGF inhibition.
Frequently Asked Questions (FAQs)
The cost of ZIRABEV 25MG/ML 4ML SDV 1/EA is $available for registerd members only
ZIRABEV 25MG/ML 4ML SDV 1/EA is manufactured by Pfizer.
You can purchase ZIRABEV 25MG/ML 4ML SDV 1/EA on our website at https://supplies.pipelinemedical.com/product/detail/zirabev-100-mg-4-ml-vial-639475